LU92902I2 - Gardasil-9/nom du produit: protéine hpv 45 l1 - Google Patents

Gardasil-9/nom du produit: protéine hpv 45 l1 Download PDF

Info

Publication number
LU92902I2
LU92902I2 LU92902C LU92902C LU92902I2 LU 92902 I2 LU92902 I2 LU 92902I2 LU 92902 C LU92902 C LU 92902C LU 92902 C LU92902 C LU 92902C LU 92902 I2 LU92902 I2 LU 92902I2
Authority
LU
Luxembourg
Prior art keywords
gardasil
product name
protein hpv
hpv
protein
Prior art date
Application number
LU92902C
Other languages
English (en)
French (fr)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of LU92902I2 publication Critical patent/LU92902I2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
LU92902C 2003-09-29 2015-12-08 Gardasil-9/nom du produit: protéine hpv 45 l1 LU92902I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50681203P 2003-09-29 2003-09-29
PCT/US2004/031326 WO2005032586A1 (en) 2003-09-29 2004-09-24 Optimized expression of hpv 45 l1 in yeast

Publications (1)

Publication Number Publication Date
LU92902I2 true LU92902I2 (fr) 2016-03-08

Family

ID=34421558

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92902C LU92902I2 (fr) 2003-09-29 2015-12-08 Gardasil-9/nom du produit: protéine hpv 45 l1

Country Status (33)

Country Link
US (2) US7250170B2 (Direct)
EP (1) EP1673106B1 (Direct)
JP (4) JP5451960B2 (Direct)
KR (1) KR101165278B1 (Direct)
CN (1) CN1859923B (Direct)
AR (2) AR045804A1 (Direct)
AT (1) ATE435029T1 (Direct)
AU (1) AU2004277934B2 (Direct)
BE (1) BE2015C072I2 (Direct)
BR (1) BRPI0414845B8 (Direct)
CA (1) CA2539168C (Direct)
CY (2) CY1110525T1 (Direct)
DE (1) DE602004021828D1 (Direct)
DK (1) DK1673106T3 (Direct)
ES (1) ES2327530T3 (Direct)
FR (1) FR15C0083I2 (Direct)
HU (1) HUS1500063I1 (Direct)
IL (1) IL174458A (Direct)
IS (1) IS2694B (Direct)
LT (2) LTC1673106I2 (Direct)
LU (1) LU92902I2 (Direct)
MX (1) MXPA06003457A (Direct)
MY (1) MY140664A (Direct)
NL (1) NL300776I2 (Direct)
NO (3) NO339932B1 (Direct)
NZ (1) NZ545834A (Direct)
PL (1) PL1673106T3 (Direct)
PT (1) PT1673106E (Direct)
RU (1) RU2360001C2 (Direct)
SI (1) SI1673106T1 (Direct)
TW (1) TWI350853B (Direct)
WO (1) WO2005032586A1 (Direct)
ZA (1) ZA200601961B (Direct)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY139500A (en) 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
DK1730175T3 (da) 2004-03-24 2010-08-23 Merck Sharp & Dohme Geoptimaliseerde expressie van HPV 52 L1 in gist
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
WO2006113209A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006114312A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
EP2059262B1 (en) * 2006-08-28 2013-08-21 Sungkyunkwan University Foundation for Corporate Collaboration A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein
US7709010B2 (en) * 2007-03-09 2010-05-04 Merck Sharp & Dohme Corp. Papillomavirus vaccine compositions
EP2479186B1 (en) * 2007-11-23 2015-08-12 Shanghai Zerun Biotechnology Co., Ltd. Genes encoding major capsid protein L1 of human papilloma viruses
KR101181907B1 (ko) 2009-06-19 2012-09-11 아이진 주식회사 자궁경부암 백신
WO2011149897A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
AU2012270418B2 (en) * 2011-06-15 2015-08-13 Posvax Co., Ltd Method for enhancing the production yield of human papillomavirus L1 protein
EP2723371B1 (en) 2011-06-24 2019-10-23 Merck Sharp & Dohme Corp. Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CN109321592A (zh) * 2012-01-21 2019-02-12 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN103361280B (zh) * 2012-03-28 2018-07-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv11 l1蛋白的方法
CN110423774A (zh) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN104120089B (zh) * 2013-04-26 2019-09-24 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN110295190A (zh) * 2013-05-17 2019-10-01 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv45 l1蛋白的方法
CN104513826B (zh) * 2013-09-29 2020-10-20 上海泽润生物科技有限公司 人乳头瘤病毒基因,及载体,菌株,表达方法
WO2015057541A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of obtaining thermostable dried vaccine formulations
BR112017004181A2 (pt) * 2014-09-11 2017-12-05 Cadila Healthcare Ltd ?gene, vetor, célula hospedeira, partículas similares a vírus, vacina para vírus de papiloma humano, composição imunogênica, adjuvante, método para o preparo de uma vacina de papiloma humano, proteína de capsídeo principal e proteína hpv l1?
CN106282278B (zh) * 2015-06-29 2021-06-08 广东东阳光药业有限公司 一种人乳头瘤病毒l1蛋白的发酵方法
CN106701798B (zh) * 2015-08-12 2021-09-17 北京康乐卫士生物技术股份有限公司 45型重组人乳头瘤病毒病毒样颗粒及其制备方法
CN109750050B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒45亚型蛋白表达
CR20220395A (es) 2020-02-14 2022-10-27 Merck Sharp & Dome Llc Vacuna contra hpv
CN112680462B (zh) * 2020-12-29 2022-02-22 上海博唯生物科技有限公司 一种人乳头瘤病毒35型/hpv35型l1/l2及其制备与应用
CN113073105B (zh) * 2021-03-23 2023-06-13 重庆博唯佰泰生物制药有限公司 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
EP4380615A1 (en) 2021-08-06 2024-06-12 Merck Sharp & Dohme LLC Hpv vaccine
EP4387660A1 (en) 2021-08-19 2024-06-26 Merck Sharp & Dohme LLC Thermostable lipid nanoparticle and methods of use thereof
US20240408188A1 (en) 2023-06-09 2024-12-12 Merck Sharp & Dohme Llc Nanoemulsion adjuvant compositions for human papillomavirus vaccines

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ336696A3 (en) * 1994-05-16 1997-07-16 Merck & Co Inc Isolated and purified proteins of papillomavirus and process for preparing thereof
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
DE69836206T2 (de) 1997-02-07 2007-08-23 Merck & Co., Inc. Synthetische hiv gag gene
WO1998054339A1 (en) * 1997-05-27 1998-12-03 Hanil Synthetic Fiber Co., Ltd. PROCESS FOR PREPARING RECOMBINANT PROTEINS USING HIGHLY EFFICIENT EXPRESSION VECTOR FROM $i(SACCHAROMYCES CEREVISIAE)
EP1002091B1 (en) 1997-07-09 2012-02-29 Coridon Pty Limited Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
US6991795B1 (en) * 1998-08-14 2006-01-31 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
JP4440471B2 (ja) * 1998-08-14 2010-03-24 メルク エンド カムパニー インコーポレーテッド ヒトパピローマウイルスのウイルス様粒子の精製方法
EP1105157B1 (en) * 1998-08-14 2006-11-02 Merck & Co., Inc. Protein delivery system using human papillomavirus virus-like particles
ATE290013T1 (de) * 1998-12-23 2005-03-15 Merck & Co Inc Neutralsierungs-assay, das humane papillomavirus- ähnliche partikel verwendet
ATE284898T1 (de) * 1999-08-25 2005-01-15 Merck & Co Inc Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
US6436402B1 (en) * 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
WO2002008435A1 (en) 2000-07-21 2002-01-31 Glaxo Group Limited Codon-optimized papilloma virus sequences
WO2003068993A1 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Method for isolation and purification of expressed gene products in vitro
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
ATE546529T1 (de) 2003-03-24 2012-03-15 Merck Sharp & Dohme Optimierte expression von hpv 31 l1 in hefe

Also Published As

Publication number Publication date
NO2017012I1 (no) 2017-04-05
ZA200601961B (en) 2007-05-30
CA2539168A1 (en) 2005-04-14
AR045804A1 (es) 2005-11-16
BRPI0414845B8 (pt) 2021-06-15
PT1673106E (pt) 2009-09-22
IL174458A (en) 2014-06-30
MXPA06003457A (es) 2006-06-05
LTC1673106I2 (lt) 2017-05-10
FR15C0083I2 (fr) 2016-11-25
TW200521233A (en) 2005-07-01
NL300776I1 (Direct) 2015-12-29
BE2015C072I2 (Direct) 2023-12-14
NO339932B1 (no) 2017-02-20
LTPA2015049I1 (lt) 2016-01-11
TWI350853B (en) 2011-10-21
RU2360001C2 (ru) 2009-06-27
JP2007507207A (ja) 2007-03-29
US20060240040A1 (en) 2006-10-26
PL1673106T3 (pl) 2009-12-31
JP5451960B2 (ja) 2014-03-26
IS8362A (is) 2006-03-20
SI1673106T1 (sl) 2009-12-31
NL300776I2 (Direct) 2015-12-29
HUS1500063I1 (hu) 2016-02-29
BRPI0414845B1 (pt) 2020-10-13
JP2016136947A (ja) 2016-08-04
DK1673106T3 (da) 2009-11-09
JP2014221052A (ja) 2014-11-27
EP1673106B1 (en) 2009-07-01
ATE435029T1 (de) 2009-07-15
US7250170B2 (en) 2007-07-31
IS2694B (is) 2010-11-15
US7482015B2 (en) 2009-01-27
IL174458A0 (en) 2006-08-01
AU2004277934A1 (en) 2005-04-14
NO2022051I1 (no) 2022-11-30
NZ545834A (en) 2009-02-28
AR077396A2 (es) 2011-08-24
CY2015050I2 (el) 2016-06-22
MY140664A (en) 2010-01-15
FR15C0083I1 (fr) 2016-08-01
CY2015050I1 (el) 2016-06-22
CN1859923B (zh) 2012-09-05
BRPI0414845A (pt) 2006-11-21
AU2004277934B2 (en) 2009-09-17
RU2006114701A (ru) 2007-11-10
CA2539168C (en) 2011-05-31
ES2327530T3 (es) 2009-10-30
US20080138361A1 (en) 2008-06-12
JP2011152137A (ja) 2011-08-11
EP1673106A1 (en) 2006-06-28
CN1859923A (zh) 2006-11-08
DE602004021828D1 (de) 2009-08-13
KR20070029628A (ko) 2007-03-14
NO20061876L (no) 2006-04-28
CY1110525T1 (el) 2015-04-29
KR101165278B1 (ko) 2012-07-23
WO2005032586A1 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
LU92902I2 (fr) Gardasil-9/nom du produit: protéine hpv 45 l1
LU92903I2 (fr) Gardasil-9/nom du produit:protéine hpv 52 l1
LU92901I2 (fr) Gardasil-9/ nom du produit: protéine hpv58l1
FR2838048B1 (fr) Produit dentaire reticulable/dereticulable
DE602004012052D1 (de) Akustisch gekoppelter Produktaufkleber
DE602004029184D1 (de) Einwegscheuerprodukt
NO20054134D0 (no) Renseprosess
ATE555190T1 (de) Wegwerfreinigungserzeugnis
FR2819718B1 (fr) Produit cosmetique
EP1970753A4 (en) IDENTIFICATION MEDIUM
SE0301552L (sv) New product
FR2877842B1 (fr) Produit aerosol anti-transpirant
GB0315248D0 (en) HCV regulated protein expression
FR2837844B1 (fr) Nouveau produit de renfort
SE0300002L (sv) Ny produkt
ITMI20031093A0 (it) Nuovi prodotti cosmetici policromi
EP1637883A4 (en) IMMUNOGROMATOGRAPHIC PROCESS
EP1384767A4 (en) LAMINATE
DK1691751T3 (da) Hygiejneprodukt
FR2861365B1 (fr) Procede de conditionnement d'un materiau isolant aere souple en le
FR2850973B1 (fr) Produit bi-composant
EP1691645A4 (en) Apparatus for concealing a product
FR2856994B1 (fr) Ensemble de distribution de produit
FR2828632B1 (fr) Produit de viennoiserie
FI5970U1 (fi) Tuotepakkaus